SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Lilly to Present Retatrutide, Taltz and Zepbound Data at ACR Meeting

Lilly says it will showcase data on the drugs at ACR Convergence 2026. The supplied body begins to describe Phase 3 TRIUMPH-1 and TRIUMPH-4 results but is truncated.

LLY

Related stories